Adding abiraterone to ADT improves survival outcomes in nonmetastatic prostate cancer

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site

Sep 19 / Springer Healthcare

Adding abiraterone to ADT improves survival outcomes in nonmetastatic prostate cancer

Oncology Prostate Cancer ESMO-2021

Description

Commentator Robert Huddart shares his thoughts on the practice-changing findings from a STAMPEDE analysis of the addition of abiraterone plus prednisolone to androgen deprivation therapy in men with high-risk nonmetastatic prostate cancer.

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.